Isis Enters Broad Collaboration With Ortho-McNeil, Inc. for the Discovery, Development and Commercialization of Antisense Drugs to Treat Metaboli... (

HOME >> BIOLOGY >> TECHNOLOGY

Isis Enters Broad Collaboration With Ortho-McNeil, Inc. for the Discovery, Development and Commercialization of Antisense Drugs to Treat Metabolic Diseases

Date:9/13/2007

- Includes license of two antisense drugs in development targeting glucagon

receptor and glucocorticoid receptor - Includes research collaboration to identify antisense drugs to inhibit

additional targets to treat metabolic diseases

- Conference call webcast Thursday, September 13, 9:45 a.m. EDT at

http://www.isispharm.com

CARLSBAD, Calif., Sept. 13 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) today announced a broad collaboration with Ortho-McNeil, Inc., a Johnson & Johnson company, to discover, develop and commercialize antisense drugs to treat metabolic diseases, including Type 2 diabetes. As part of the collaboration, Isis will grant to Ortho-McNeil worldwide development and commercialization rights to two of its diabetes development candidates, ISIS 325568 and ISIS 377131, which selectively inhibit the production of glucagon receptor (GCGR) and glucocorticoid receptor (GCCR), respectively. Additionally, Ortho-McNeil will provide funding to Isis to support the joint discovery of novel drugs to treat metabolic diseases, including diabetes and obesity. After the initial collaboration phase, Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD) will continue development of these drugs.

Ortho-McNeil will pay Isis a $45 million upfront licensing fee, and will provide Isis with research and development funding over the period of the collaboration. In addition to the licensing fee, Isis could receive over $230 million in milestone payments upon successful development and regulatory approvals of ISIS 325568 and ISIS 377131, as well as royalties
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5
Related biology technology :

1. WARF enters licensing agreements for stem cell products
2. Virent enters agreement with Shell Oil unit to make hydrogen with biomass
3. Software company enters health space with RFID solutions on hold
4. Lucigen Corp. enters global licensing agreement
5. Call centers and customer service: The good, the bad, and the clueless
6. GE Healthcare enters agreement with Canadian health authority
7. Data centers: Buyers beware of over-hyped facilities
8. Data centers: Blowing smoke and raising red flags
9. Prodesse enters patent agreement with Roche
10. UW-Madison enters Kauffman grant competition
11. Applied Technology Centers to aid printing and manufacturing

Post Your Comments:

(Date:11/7/2009)...RNewswire/ -- Research projects in the areas of ma...vening, as Tim Kunisky of Livingston, NJ and the t...on, PA received the highest honors at the Region F..., Science & Technology, the nation,s premier h...w.newscom.com/cgi-bin/prnh/20070904/SIEMENSLOGO ...

(Date:11/6/2009)...swire/ -- Myriant Technologies LLC ("Myriant"), a ... of renewable bio-chemicals, Uhde Corporation of ... GmbH, one of the world,s leading engineering cont...r the engineering, procurement & construction ...ased on renewable feedstocks. The execution of th...

(Date:11/6/2009)...FirstCall/ - Oncolytics Biotech Inc. (TSX:ONC, NAS...nounced updated results from a Phase II study of i...etastatic to the lung in a poster presentation at ... Meeting held in Miami Beach, Florida, from Novemb...A Phase II Study of Intravenous REOLYSIN (Wild-typ...

(Date:11/5/2009)...RNewswire-FirstCall/ -- GenVec, Inc. (Nasdaq: GNV...third quarter ended September 30, 2009. GenVec rep... for the three months ended September 30, 2009 com...re) in the comparable quarter of 2008. For the nin...ss was $14.1 million ($0.15 per share), compared t...

Breaking Biology Technology:Mathematics and Biochemistry Research Earn Top Prize at Nation's Premier High School Science Competition 2 Mathematics and Biochemistry Research Earn Top Prize at Nation's Premier High School Science Competition 3 Mathematics and Biochemistry Research Earn Top Prize at Nation's Premier High School Science Competition 4 Mathematics and Biochemistry Research Earn Top Prize at Nation's Premier High School Science Competition 5 Mathematics and Biochemistry Research Earn Top Prize at Nation's Premier High School Science Competition 6 Myriant Technologies LLC, Uhde Corporation of America and Uhde GmbH Announce Alliance for Engineering, Procurement & Construction of World Scale Renewable Succinic Acid Plants 2 Myriant Technologies LLC, Uhde Corporation of America and Uhde GmbH Announce Alliance for Engineering, Procurement & Construction of World Scale Renewable Succinic Acid Plants 3 Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting 2 Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting 3 GenVec Reports Third Quarter 2009 Financial Results 2 GenVec Reports Third Quarter 2009 Financial Results 3 GenVec Reports Third Quarter 2009 Financial Results 4 GenVec Reports Third Quarter 2009 Financial Results 5 GenVec Reports Third Quarter 2009 Financial Results 6

[0] Mathematics and Biochemistry Research Earn Top Prize at Nation's Premier High School Science Competition [1] Myriant Technologies LLC, Uhde Corporation of America and Uhde GmbH Announce Alliance for Engineering, Procurement & Construction of World Scale Renewable Succinic Acid Plants [0] Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting [0] GenVec Reports Third Quarter 2009 Financial Results

...h 13 ,Cellectis SA (NYSE: ALCLS ), a world leader...y that it filed a patent infringement lawsuit agai...es District Court for the,Eastern District of Nort...y making and selling certain meganucleases, Precis...lating to its proprietary meganuclease,recombinati...

.../ - Angiotech Pharmaceuticals,Inc. (NASDAQ: ANPI ...,medical device company, today announced the filin... and Management,s Discussion and Analysis,for the ...f its audited,consolidated financial statements fo... ended December 31, 2007, the Company,s net loss a...

...c.,(Nasdaq: BNVI ) announced today the appointmen...of Directors. Dr. Butler has extensive regulatory,...es, and in particular in,advancing cancer drug dev...d to have George on board as we move into a new,ph...linical trial,programs," said Isaac Cohen, O.M.D.,...

Cellectis Sues Precision BioSciences for Infringement of its Patents Concerning Meganuclease Technology Angiotech announces filing of audited financial results for the year ended December 31, 2007 and restatement of results for the year ended December 31, 2006 George Butler Joins Bionovo's Board of Directors

(Date:11/4/2009)...g Beach and Riverside are responsible for a signif...and the true impact of air pollution and ship emis...d, according to researchers at the University of S...pears in an online edition of the American Journa...f all childhood asthma cases in Long Beach and six...

(Date:11/4/2009)... DNA codes, or genomes, of the famed fugu (or puff...10K Project, an international effort to build an i...ecies of animals for conducting comparative studie..., Participating in The Genome 10K project, descri... of the Journal of Heredity , are 70 leading scie...

(Date:11/4/2009)...Call/ -- Quest Diagnostics Incorporated (NYSE: DG...sting, information and services, announced that fo...me from continuing operations rose to $192 million...r $0.81 per diluted share, for the third quarter o...d by a $0.03 per share charge associated with the ...

[0] USC study finds big air pollution impacts on local communities [0] Singapore scientists join international study of 10,000 vertebrates' genomes [0] Quest Diagnostics Reports Strong Performance in Third Quarter 2009

...ry 1st issue of G&D, Drs. Thomas Mullen and Willia... the degradation of mammalian histone,mRNA. Histo... but the,mechanism by which this occurs has remain...e, conserved 3, stem-loop structure rather than th...ff demonstrate that uridine,residues are added to ...

...c. 28, 2007) -- A research team at Weill Cornell M... genes that may be crucial to the production of an...10). , The discovery fills in an important "mis...en tied to disorders ranging from lupus and Type 1...n has to be kept in a delicate balance for health,...

...deep-sea species poses a severe threat to the futu... early online on December 27th and in the January ...l Press. In a global-scale study, the researchers ...f the deep sea, as measured by the rate of critica...h the diversity of species living there. , For th...

Other Biology News:2 genes are important key to regulating immune response 2 2 genes are important key to regulating immune response 3 Deep-sea species' loss could lead to oceans' collapse, study suggests 2

Oliguridylation-mediated histone mRNA decay 2 genes are important key to regulating immune response Deep-sea species' loss could lead to oceans' collapse, study suggests

...ular Localization Kit with TransIT-siQUEST Transfe... to directly label and deliver siRNA, of your desi...r in vitro tracking experiments. Subcellular local...xpression can be monitored following introduction ...

...atrix (ECM) is an important step in tumor metastas... and spreading along the blood vessel wall. Prote... tiny holes in the sheath-like covering (basement ...ancer cells to invade.,The CHEMICON Cell Invasio...

Corning Cryo Box, 81 Position, 4-5 ml, Non-Sterile from Sigma-Aldrich

MACS Protein A/G Starting Kit from Miltenyi Biotec

Biology Products:

Label IT siRNA Tracker CX Rhodamine Kit with TransIT-siQUEST Reagent from Mirus Bio Corporation Cell Invasion Colorimetric Assay Kit from CHEMICON Corning Cryo Box, 81 Position, 4-5 ml, Non-Sterile from Sigma-Aldrich MACS Protein A/G Starting Kit from Miltenyi Biotec

Isis Enters Broad Collaboration With Ortho-McNeil, Inc. for the Discovery, Development and Commercialization of Antisense Drugs to Treat Metaboli...( - Includes license of two antisense d...)